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Abstract
Background: Extranodal NK/T-cell lymphoma (ENKTCL) reports from sub-Saharan Africa (SSA) are remarkably rare,
despite early childhood acquisition and high prevalence of the causative infectious agent, Epstein-Barr virus (EBV),
and frequent occurrence of other lymphoproliferative disorders causally associated with EBV.
Case presentations: At a national teaching hospital in Malawi, three patients of African descent were seen with
ENKTCL between 2013 and 2014. Patients were aged between 29 and 60 years, two with craniofacial involvement
and one with a primary abdominal tumor, and all were HIV-negative. All had systemic B symptoms, and two severely
impaired performance status. On histologic review, morphology and immunophenotyping demonstrated classical
ENKTCL features in all cases, including diffuse proliferations of intermediate-to-large atypical lymphocytes with high
mitotic activity and extensive background necrosis, positivity for CD3 and CD56, and negativity for CD20. By in situ
hybridization, all three tumors were positive for EBV-encoded RNA (EBER). Baseline plasma EBV DNA was also markedly
elevated for all three patients. Due to radiotherapy and chemotherapy limitations, patients were treated with CHOP
(cyclophosphamide, doxorubicin, vincristine, prednisone) with rapid disease progression. All three patients died from
progressive lymphoma within 3 months of initial diagnosis.
Conclusions: Our experience with these three patients in Malawi can highlight that ENKTCL does indeed occur in SSA,
increase familiarity with ENKTCL among clinicians and pathologists throughout the region, and emphasize the need for
better diagnosis and treatment for this neglected population.
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Background
It is vital to improve lymphoma diagnostic infrastructure
in sub-Saharan Africa (SSA) to fully understand the het-
erogeneity of non-Hodgkin lymphoma (NHL) in the re-
gion, provide better prognostic information to patients
and clinicians, and allow more subtype-directed therapy
where appropriate. In resource-rich settings, molecular
profiling is increasingly leading to tailored therapeutic
approaches even within well-defined histologic categor-
ies, like diffuse large B-cell lymphoma. However, due to
resource limitations in SSA, the entire spectrum of NHL
is often diagnosed and treated as a single entity. Among
low- and middle-income countries, extranodal NK/T-cell
lymphoma (ENKTCL) in particular has been principally
described in Asia and Latin America, and published re-
ports from SSA are remarkably few. This is despite early
childhood acquisition and high prevalence of the causa-
tive infectious agent, Epstein-Barr virus (EBV), in SSA,
as well as frequent occurrence of other lymphoprolifera-
tive disorders that are causally associated with EBV, like
endemic Burkitt lymphoma and classical Hodgkin
lymphoma. Therefore, to increase regional awareness of
this disease, highlighting the occurrence of ENKTCL
specifically in SSA is important.
Case presentations
At a national teaching hospital in the capital of Malawi,
Lilongwe, three patients of African descent were seen with
ENKTCL between September 2013 and March 2014, and
were enrolled in the prospective Kamuzu Central Hospital
Lymphoma Study cohort after informed consent. Case 1
was a 29-year-old male with a greater than 6 month
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history of an abdominal mass. Case 2 was a 51-year-
old male who presented with a 4 month history of a
sinonasal tumor eroding the medial wall of the max-
illa associated with right eye proptosis. Case 3 was a
60-year-old female with a less than 3 month history
of progressive left maxillary sinus mass involving the
medial left and right orbits. All three patients were
HIV-negative, all had systemic B symptoms, and two
had severely impaired Eastern Cooperative Oncology
Group performance status of greater than 2.
Biopsy and tumor characterization using immunohisto-
chemistry performed locally in Lilongwe was done for all
patients, and was reviewed in real time during a weekly tel-
epathology conference conducted between clinicians and
pathologists in Lilongwe and Chapel Hill, as previously de-
scribed in detail [1]. Histologically, all three cases showed
diffuse proliferations of intermediate-to-large atypical lym-
phocytes with high mitotic activity and areas of extensive
background necrosis, as shown for a single case exhibiting
features typical of all three in the accompanying Fig. 1.
Immunophenotypically, the tumors were all positive for
CD3 and CD56, and negative for CD20. Subsequent in situ
hybridization (ISH) in Chapel Hill demonstrated all three
tumors to be positive for EBV-encoded RNA (EBER). All
patients had staging bone marrow evaluations without in-
volvement by lymphoma.
Other baseline laboratory investigations were nor-
mal excepting mild anemia (hemoglobin 10.8 g/dL) in
one case, and elevated lactate dehydrogenase in two
cases. Baseline plasma EBV DNA was also markedly
elevated for all three patients by real-time quantitative
polymerase chain reaction, ranging from 3412 to
2,098,940 copies/mL. Radiotherapy is currently not
available anywhere in Malawi, and limited supportive
care infrastructure and low drug availability prohibit
intensive chemotherapy regimens including asparagi-
nase or high-dose methotrexate. Therefore, the local
standard of care for most NHL subtypes is CHOP
(cyclophosphamide, doxorubicin, vincristine, prednis-
one). Of our three patients, one was too sick to initi-
ate cytototoxic treatment and two received a single
dose of CHOP with rapid subsequent disease progres-
sion. All three patients died from progressive lymph-
oma within 3 months of initial diagnosis.
Discussion and conclusions
ENKTCL is an uncommon subtype of the the mature T
and NK-cell neoplasms, a heterogeneous group of ag-
gressive NHL that account for approximately 12% of all
NHL in the United States, Europe, and Asia [2].
ENKTCL typically involves the upper aerodigestive tract,
with the nasal cavity being the prototypic site of
Fig. 1 Biopsy of sinonasal mass from Case 2. a Ulcerated squamous mucosa surrounded by necrosis and subepithelial proliferation of tumor cells
(haematoxylin and eosin, 10×). b Moderate-to-large atypical lymphoid-appearing tumor cells with high mitotic activity (haematoxylin and eosin, 40×).
c Tumor cells positive for CD56 by immunohistochemistry (40×). d Tumor cells positive for Epstein-Barr virus-encoded RNA by in situ
hybridization (40×)
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involvement. Sites for extranasal involvement include
skin, soft tissue, gastrointestinal tract, and testes [3]. Our
cases highlight the rapid clinical progression of this dis-
ease and short overall survival, particularly after subopti-
mal treatment as in our setting. Importantly, CHOP was
administered in our setting due to lack of more suitable
alternatives like aparaginase or high-dose methotrexate,
and poor outcomes after CHOP for ENKTCL are have
been attributed to tumor expression of multidrug resist-
ance protein [4].
There is significant ethnic and regional variation in
ENKTL prevalence worldwide. It is most common in
East and Southeast Asia, as well as regions of Central
and South America, where it has been reported to repre-
sent 6–15% of NHL cases [5–7]. Frequency in SSA and
persons of African descent is not extensively described,
but is presumed to be low, although this may reflect
under-recognition and under-diagnosis given well docu-
mented diagnostic limitations in the region. Retrospect-
ive epidemiologic studies in the United States have
found non-Hispanic black persons to account for 2 to
5% of all ENKTCL cases [8]. There are also a very small
number of published reports of ENKTCL in SSA [9–11],
in addition to other studies describing NHL of the nasal
cavity and nasopharynx without complete histopatho-
logic or immunophenotypic characterization [12, 13].
Pathologically, ENKTCL most commonly expresses an
NK cell phenotype, being positive for CD56, cytoplasmic
CD3ε+, without surface T-cell receptor (TCR) and TCR
gene rearrangements [2, 14]. A subset of cases may dem-
onstrate a T-cell phenotype with clonal TCR gene rear-
rangements. ENKTCL is strongly associated with EBV,
which can be uniformly demonstrated in tumors by
EBER ISH and plasma by qPCR [15, 16]. Plasma EBV
DNA is correlated with other markers of disease severity
like clinical stage and serum lactate dehydrogenase.
Plasma EBV DNA levels at baseline are also associated
with clinical outcomes, and serial measurement may be
valuable for assessing response to treatment [16].
In conclusion, although EBV is highly prevalent in SSA
with acquisition typically during early childhood, and
other EBV-associated lymphoproliferative disorders in-
cluding endemic Burkitt lymphoma and classical Hodgkin
lymphoma are often described, ENKTCL reports from
SSA are scarce, likely reflecting under-diagnosis. We hope
our experience with these three patients in Malawi can
serve to highlight that ENKTCL does indeed occur in
SSA, increase familiarity with ENKTCL among clinicians
and pathologists throughout the region, and emphasize
the need for better diagnosis and treatment for this
neglected population.
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